Introduction
Glioblastomas (GBMs) account for approximately 12-15% of all intracranial human neoplasms and 50-60% of all astrocytic tumors (Davis et al., 2001) . A main characteristic of GBMs is their extreme migrational potential (Berens and Giese, 1999) . They appear to invade normal brain along the white matter tracts, around nerve cells, and along perivascular spaces. The classical therapeutic triad for malignant brain tumors includes neurosurgery, radiation, and chemotherapy, while novel immunotherapeutic approaches that target antigens involved in angiogenesis, migration, and/or growth factor receptors have recently shown promise in clinical trials (Brown et al., 1996; Bigner et al., 1998) . To rapidly identify novel targets for immunotherapeutic approaches, we have employed a strategy that combines subtractive cloning with cDNA array screening for target identification. Whereas commercially available arrays used to profile brain tumors contain genes mostly unrelated to the disease of interest, our arrayed clone collection is derived from a subtractive cDNA enrichment process and therefore selects for transcripts expressed in glioblastomas (Rhee et al., 1999; Huang et al., 2000) . Furthermore, we took a two-step array analysis approach to increase the statistical significance of array-based target selection: in the first step, highdensity arrays containing clones derived from our subtractive and normalized cDNA libraries were probed with various tumor and control samples. In a subsequent step, all clones identified as transcriptionally induced in the first analysis were newly arrayed at lower density and probed to confirm their transcriptional regulation ( Figure 1 ). To identify the underlying genes corresponding to clones identified as specifically induced in brain tumor samples, recombinant inserts of those clones were sequenced and a nonredundant collection of gene identifiers assembled by comparison to public domain and proprietary databases. In summary, our array design and clone selection criteria ensured the generation of a disease-relevant collection of differentially expressed genes from human brain tumors for further functional studies.
We used the approach outlined above to profile the expression patterns of 14 individual GBMs. We identified over 200 genes that are overexpressed in human brain tumors compared with normal brain. One of these genes is the receptor tyrosine phosphatasez (RPTPz) also known as RPTPb (Krueger and Saito, 1992; Levy et al., 1993) . RPTPz is a member of a diverse class of protein tyrosine phosphatases (PTPs) consisting of both cytoplasmatic PTPs and transmembrane, receptor-like PTPs (RPTP). Whereas most PTPs are expressed in peripheral tissues and the central nervous system (CNS), RPTPz expression is restricted to the CNS (Levy et al., 1993) . Interestingly, the highest levels of RPTPz expression in both the developing and the adult mouse brains occur in those regions that have the greatest mitotic potential; that is, the embryonic ventricular and subventricular zones and the dentate gyrus and subependymal layer of the anterior horn of the lateral ventricle.
Three splice variants of RPTPz have been described: a full-length 9.4 kb transmembrane form, a short 6.4 kb transmembrane form, and soluble 8.4 kb form, which is also known as 6B4 proteoglycan/phosphacan (Levy et al., 1993) . To date, little is known about the regulation of RPTPz activity by alternative splicing. Various cell-adhesion molecules (e.g. Nr-Cam, Contactin, L1/NgCam) and extracellular matrix molecules (e.g. tenascin C) are known to bind to RPTPz's extracellular domain; however, the downstream signaling events await further elucidation (Grumet et al., 1994; Adamsky et al., 2001) . The first soluble ligand of RPTPz, pleiotrophin (Ptn), was recently described (Meng et al., 2000) . Upon binding, Ptn inactivates the phosphatase activity of RPTPz, which leads to an increased tyrosine phosphorylation status of important downstream signaling molecules like b-catenin (Meng et al., 2000) .
Since the phosphorylation status of tumor cells plays an important role in regulating GBM invasiveness and proliferation (Dirks and Rutka, 1997; Besson et al., 2001) , we investigated the role of RPTPz and its ligand Ptn in GBM cells. Our results establish that RPTPz mRNA and protein are overexpressed in GBMs and indicate that RPTPz expression plays an important role in the regulation of GBM cell motility.
Results

Identification of differentially expressed genes
To identify novel therapeutic target genes, cDNA array expression profiling was performed using primary tissue from human GBM and normal brain (Figure 1 ). Disease-specific screening arrays containing B25 000 clones were generated by isolating recombinant clone inserts derived from cDNA libraries enriched for brain tumor-relevant transcripts through normalization and subtraction. Since array analysis inherently has high intrinsic noise, determination of fold induction derived from a single array experiment represents a poor guide for collection of induced genes. We therefore selected clones based on consistent elevation of expression in multiple experiments and biological specimens. Consequently, screening arrays were hybridized with 14 individual GBM and five normal human brain control probes. In our analysis of these screening arrays, 1100 clones were induced 4twofold in two or more tumor samples including the receptor PTP zeta and Ptn. RPTPz was induced 41.5-fold in four tumor probes (ranging from 1.62 to 4.08, Po0.05, Student's t-test). Ptn was upregulated in seven tumor probes (ranging from 2.3 to 15.37, Po0.05, Student's t-test).
Recombinant inserts of these clones were spotted in triplicate on a newly designed array, the 'confirmatory array', and hybridized in two replicate experiments with newly labeled probes derived from the same mRNA used in the initial screen. In the confirmatory array screen, we analysed eight GBM samples and compared them to five normal brain controls. The triplicate measurement in two independent experiments of the confirmatory array screen produced more consistent data points per clone and therefore allowed us to perform a more rigorous statistical analysis compared to the screening arrays. Therefore, we were able to lower the threshold for statistically significant induction to 41.2-fold with significant P-values (Po0.05) to screen for upregulation (see Materials and methods section for details). From these confirmatory arrays, 860 clones were derived and the cDNA inserts of these clones were sequenced and subjected to a comprehensive homology analysis. Thus, a nonredundant collection of 218 genes was assembled and annotated. In our analysis of the confirmatory array screen, RPTPz was upregulated in six tumor samples out of eight ranging from 1.53 (P ¼ 0.0047) to 1.76 (Po0.0001), compared to normal brain controls. Ptn was induced in seven out of eight tumor samples ranging from 1.65 (Po0.0001) to 2.41 (Po0.04). Other genes transcriptionally induced included brevican, tenascin, cmet receptor, CD44, osteopontin and secreted protein acidic and rich in cysteine (SPARC) as previously reported by others (Gary and Hockfield, 2000; Huang et al., 2000; Kim et al., 2000; Oz et al., 2000) .
RPTPz expression analysis
The confirmatory arrays revealed that both RPTPz and its primary soluble ligand, Ptn, were overexpressed in GBM relative to normal brain. To corroborate our findings on cDNA arrays and to obtain independent confirmation of RPTPz upregulation in GBM, we investigated RPTPz expression by Northern blot analysis ( Figure 2) . As a result, all six GBMs tested showed induced expression of RPTPz compared to normal brain and astrogliotic tissue. While all the three RPTPz splice variants (6.4, 7.5, and 8.8 kb) are expressed in GBMs and normal brain, the short 6.4 kb transmembrane form appears more abundant in tumor samples than in normal brain. Semiquantitative, densitometric analysis of the Northern blot revealed a 4.74-fold-average upregulation of RPTPz in all the six GBMs tested relative to the expression in normal brain and astrogliotic tissue. The elevated expression of RPTPz in GBM compared to normal human brain tissue was further confirmed by quantitative RT-PCR (data not shown). We next analysed the localization of protein expression of RPTPz by immunohistochemistry on paraffin-embedded sections of primary tumors ( Figure 3 ). GBM tumor cells from separately biopsied samples stain intensely immunoreactive for RPTPz (Figure 3a, b) . This pattern is in sharp contrast to the weak staining found in cortical neurons ( Figure 3c ) and the complete absence of staining in white matter ( Figure 3d ). Consistent with our array and Northern blot analysis, these results clearly demonstrate the upregulation of RPTPz protein in GBM. In summary, we have identified RPTPz as a gene overexpressed in GBMs based on its mRNA and protein expression profile in human brain tumors.
Knockdown analysis of RPTPz
To identify its functional role in human brain tumors, we tested the response of GBM tumor cells to RPTPz downregulation in vitro. We investigated the effect of reduced expression of RPTPz in two human GBM cell lines, G122 and D566. Both cell lines were derived from primary GBMs. To specifically reduce RPTPz mRNA abundance in these cells, we used short interfering RNA technology (siRNA) (Elbashir et al., 2001; Paddison et al., 2002) . At 24 h following siRNA transfection, Western blot analysis of whole-cell protein lysates using a RPTPz-specific antibody demonstrated a 73% reduction of RPTPz protein. Reduction of RPTPz expression was specific, as the unrelated sequence control siRNA had no detectable effect on RPTPz expression compared to mock-transfected cells (Figure 4a ). SiRNA can therefore be used in cultured human GBM cells to specifically knock down the expression of RPTPz.
We next examined the migrational behavior of GBM cells with reduced RPTPz expression. We consistently observed a statistically significant reduction in the , two specimens of astrogliotic tissue adjacent to arterio-venous angiomas (A1, A2), six GBMs (G1-G6), GBM cell line U373 and NIH/3T3 fibroblasts (3T3). The lower part of the figure shows a loading control with clearly discernible 28S and 18S RNA bands. Compared to normal brain and astrogliotic tissue, RPTPz mRNA expression is strongly increased in GBMs, and in most cases the short form (RPTPz-B: 6.4 kb) is the most predominant splice variant. The band at 8.8 kb corresponds to the long form (RPTPz-A), and the band at 7.5 kb corresponds to the secreted form, which is also known as phosphacan. As a control for RPTPz expression, we used mRNA from U373-cells, and mRNA from NIH/3T3 cells was used as the negative control. Semiquantitative densitometric analysis revealed the following expression levels of RPTPz in ratio to rRNA: N1: 0.22, N2: 0.23, A1: 0.06, A2: 0.15, GBM1: 0.86, GBM2: 0.76, GBM3: 1.60, GBM4: 1.00, GBM5: 1.32, GBM6: 1.29. (b) Northern blot analysis of different GBM cell lines (G84, D566, and G122) used for functional studies described below. In cell lines D566 and G122, all the three splice variants are expressed, whereas in the GBM cell line, G84, no RPTPz variant is expressed Role of RPTPf in glioma cell migration S Müller et al migration of G122 and D566 cells transfected with siRPTPz in a modified Boyden chamber assay compared to control siRNA or mock-transfected cells (Figure 4b ). These findings strongly suggest that the expression of RPTPz has a significant influence on the migrational behavior of two independent GBM cell lines.
Stimulation of different GBM cell lines with Ptn
Since Ptn is RPTPz's predominant ligand and its mRNA is also overexpressed in GBM compared to normal brain in our array analysis, we investigated the influence of Ptn signaling on the migrational behavior of GBM cells. For this study, we selected the GBM cell line G84 that does not express detectable levels of RPTPz and D566, which strongly expresses RPTPz (data not shown). Upon stimulation with Ptn, we observed a remarkable and concentration-dependent increase in migration for the D566 cell line (Figure 5a ), while the migrational behavior of G84 did not change with any of the Ptn concentrations tested. From all Ptn concentrations tested, maximal stimulation was detected at a Ptn concentration as low as 5 ng/ml culture medium. We further analysed the response of D566 cells to Ptn stimulation following suppression of RPTPz expression by siRNA. Consistent with the hypothesis that PtnRPTPz signaling enhances migration of GBM, cells with reduced expression of RPTPz did not respond to Ptn stimulation with increased migration (Figure 5b ). However, D566 cells with unaltered RPTPz expression showed an increase in migrational behavior. These findings suggest that signaling of Ptn through RPTPz stimulates migration of GBM cells. 
RPTPz and proliferation of GBM cells
Protein tyrosine phosphorylation plays an important role in cellular processes such as cell motility and proliferation. Several receptor kinases such as the TRK receptor family, EGF receptor, and several others have been implicated in the proliferation of GBM cells. We therefore studied the possible role of RPTPz on the proliferation of GBM cells. We determined the proliferation rate of GBM cells that were either stimulated with Ptn or incubated with siRNA specific for RPTPz. Under both conditions, we did not observe any changes in cell proliferation (data not shown). These results indicate that RPTPz is not part of a signaling cascade influencing the proliferation of GBM cells.
Discussion
We applied genomic technologies to the analysis of human GBMs with the goal of identifying and subsequently functionally characterizing gene products that are involved in human brain tumors. To that end, we generated cDNA libraries that are highly enriched for GBM-expressed transcripts. We selected candidate genes for further biological analysis, based on their transcriptional induction in primary GBMs relative to normal human brain samples. To increase the confidence in array-based selection of candidates, we employed a staged selection scheme that confirms transcriptional induction on multiple arrays with multiple tissue samples as probes. Out of the 200 genes identified in our study, several were previously implicated in GBMs. As examples, brevican and tenascin are components of the extracellular matrix (ECM) and are involved in glioma invasion (Zhang et al., 1998) . Antitenascin-131 I labeled antibodies recently entered clinical trials and showed promising therapeutic effects in GBM patients (Bigner et al., 1998) . Similarly, anti-CD44 and anti-met receptor antibodies led to significantly reduced tumor mass in a mouse model of GBM (Oz et al., 2000; Cao et al., 2001) . Furthermore, functional studies overexpressing SPARC resulted in a more invasive behavior of glioblastoma cells (Menon et al., 2000) .
Since we were especially interested in finding novel target genes to develop immunotherapeutic antibodies, we defined stringent criteria for selecting genes for further functional studies from the large data sets generated by cDNA arrays. Specifically, we screened for transmembrane proteins that were overexpressed in more than two out of 14 GBM samples investigated compared to normal brain. We identified RPTPz as one promising candidate. The extracellular domain of RPTPz binds various ECM molecules (tenascin-C, tenascin-R) (Grumet et al., 1994) , growth factors (Ptn, midkine, fibroblast growth factor-2) (Maeda and Noda, 1998) , and cell adhesion molecules (Nr-cam, Ng-Cam/contactin) (Revest et al., 1999) . Most of these genes were also found by our array analysis. Of these, Ptn showed the strongest induction in most tumor samples investigated. These findings indicate that Ptn signaling through RPTPz may play an important role in GBMs. To date, little is known about the intracellular signaling of RPTPz. Recent studies revealed a potential interaction with members of the catenin family, PSD-90 family, sodium channel, and G-protein-coupled receptor kinase interactor (Kawachi et al., 1999 (Kawachi et al., , 2001 . With the goal of identifying and characterizing immunotherapeutic antibody targets, we focused our functional studies on the role of RPTPz and Ptn signaling.
RPTPz signaling has been implicated in the migration of astrocytes during development (Maeda et al., 1995) and in the migration of Schwann cells as well as osteoblasts (Thomaidou et al., 2001 ). More recently, RPTPz was shown to be the receptor for tenascin on glial tumor cells (Adamsky et al., 2001) . Interactions of tumor cells with the ECM are important for the invasive behavior for tumor cells. Here we correlated the expression of RPTPz with phenotypic characteristics of GBM cells. We demonstrated the efficient knockdown of gene expression by siRNA in GBM cell lines and used this experimental system to unravel a previously unknown role for RPTPz in the migration of brain tumor cells. We were able to show that the migration of GBM cells is influenced by a concentration-dependent stimulation of the Ptn-RPTPz signaling pathway. In addition, cells with no detectable RPTPz expression did not respond to Ptn stimulation in our migration assay. We also showed that suppression of RPTPz expression reduced the stimulatory effect of Ptn on cellular migration. Collectively, our results suggest that the Ptn-RPTPz signaling pathway is involved in the regulation of GBM cell motility.
In summary, we identified RPTPz as a key player for GBM cell migration by a strategy that integrated custom disease-specific cDNA libraries with custom cDNA arrays for expression profiling and cell-based assays for functional analysis of selected gene products. Our results provide strong evidence that the RPTPz pathway plays an important role in the ability of GBM cells to migrate and points to the therapeutic utility of RPTPz or other molecular components of that pathway for the treatment of brain tumors.
Materials and methods
Tissues and cell lines
GBM cell lines G122 and G84 used in this study are described elsewhere (Westphal et al., 1994) . GBM cell line D566 is a kind gift of D Bigner, Duke University, NC, USA. G122 cells were maintained in Earle's minimum medium, supplemented with 2 mm glutamine, 1 mm pyruvate, 2.5 mmol/ml amphotericinB (Gibco, Carlsbad, CA, USA) and 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA) if not indicated otherwise. D566 cells were cultivated in MEM zinc option media supplemented with 10% FBS. GBM and other tumor samples were collected at the Department of Neurosurgery, University Hospital Eppendorf, Hamburg. All surgical specimens were frozen quickly in liquid nitrogen and kept at À801C. Each tumor sample was histologically analysed by the Department of Neuropathology, University Hospital Eppendorf, Hamburg, and processed according to hospital internal review guidelines. The normal human brain and fetal brain mRNA used as control were obtained from commercial sources (Clontech, Palo Alto, CA, USA; Invitrogen, Carlsbad, CA, USA).
Tissue processing and preparation of RNA Total RNA of cells and tumor samples was isolated by homogenization in Tri Star reagent (Invitrogen, Carlsbad, CA, USA) using the acid-guanidinium method followed by phase separation with chloroform and precipitation with isopropanol. The resulting RNA was treated with RNAse-free DNAse (Ambion, Austin, TX, USA) for 40 min at 371C. Messenger RNA isolation was carried out using Oligotex (Qiagen, Chatsworth, CA, USA). Denaturing agarose gel electrophoresis was used to assess the integrity and purity of mRNA preparations.
Subtracted/normalized cDNA library construction and probe generation for array analysis Reverse transcription and second-strand synthesis were performed using the Superscript II reverse transcription kit (Invitrogen, Carlsbad, CA, USA) with an anchored Oligo dT (30) primer. Using suppression PCR, subtractive and normalized cDNA libraries were generated as described (Diatchenko et al., 1996) . Hybridization conditions were adjusted to the type and amount of tissue for best subtraction results. Doublestranded cDNA (ds-cDNA) was digested with RSA I (New England Biolabs, Beverly, MA, USA), purified and labeled with 33 P-dCTP (Perkin-Elmer Lifesciences, Boston, MA, USA) using a Decamer labeling kit (Ambion, Austin, TX, USA) to generate probes for hybridization.
Array production and hybridization
Normalized/subtracted cDNA libraries were cloned into the pCR2.1. vector using a TA cloning kit (Invitrogen, Carlsbad, CA, USA). Libraries were plated on LB-Amp, X-Gal, IPTG plates to a density of 3000 clones/24 Â 24 cm 2 plate. Using an automated colony picker (Q-Pix, Genetix, Cambridge, UK), single colonies were picked into 384-well plates and incubated for 16 h at 371C. PCR was performed using Hot Start polymerase (Qiagen, Chatsworth, CA, USA) and vectorspecific primers (M13forward and M13reverse). PCR products were visualized on a 1.5% agarose gel and spotted on Nylon membranes using a 384 pin head arrayer (Q-bot, Genetix, Cambridge, UK). For screening high-density arrays, 25 000 individual clones along with standards and empty wells were spotted onto a single filter and three membrane filters were hybridized per probe in each of two independent experiments. Hence, each screening array experiment consisted of triplicate samples hybridized with freshly labeled probes derived from the same tumor and control mRNA sources. For the confirmatory arrays, up to 1563 clones including controls were spotted in triplicate in separate spatial fields onto a single filter (hence 4608 spots per filter) and hybridized with newly labeled probes derived from the same mRNA sources. The spotted PCR products were crosslinked to the membrane by UV light. Filters were denatured and neutralized using standard protocols. Hybridization was performed at 421C for 24 h, in a hybridization solution containing 50% formamide.
Array analysis
After densitometry of the 33 P signal using a Cyclone phosphorimaging system (Packard Biosciences, Meriden, CT, USA) and GenePix software analysis (Axon Instruments, Foster City, CA, USA), individual data points were normalized to the global background signal, which was calculated from 1100 empty positions on the array. For the screening arrays, the mean and standard deviation from triplicate measurements per experiment for each clone were determined to calculate the confidence level (Student's t-test) and ratio of expression between tumor and control tissue for each experiment. Clones that were upregulated more than twofold in two replicate experiments in the screening arrays at a confidence level greater than 95% (Student's t-test) were newly arrayed in triplicate (the 'confirmatory arrays'). These arrays were subsequently hybridized in two independent experiments with probes newly labeled from the same mRNA sources used in the screening experiment. Prior to statistical analysis, the raw values for the confirmatory array data were log 2 þ 1 transformed to improve normality. Subsequently a three-step analysis was performed. The first analysis was an ANOVA (Partek, St Charles, MO, USA) of all GBM and normal samples for each clone. This step illuminated clones showing significant behavior among all samples arrayed. The second step was a pairwise comparison of each GBM to control using the Tukey-HSD test. This step allowed for determination of the pairwise comparisons to be made while controlling the experimentwise error rate, therefore limiting Type-I errors. The third step was a ratio calculation of the normalized and transformed expression values for each tumor and control comparison (Butte, 2002) . The ratios (i.e. folds) were reported with their associated propagated error and P-value. From this confirmatory array analysis, clones, which showed significant and consistent upregulation (i.e. fold value 41.20, P-value o0.05) in at least two GBMs, were selected and subsequently sequenced.
Sequencing
Sequencing reactions were carried out using vector-specific M13 forward and M13 reverse primers. The reactions were set up using ABI PRISM s BigDyet Terminators v 3.0 (PerkinElmer, Forster City, CA, USA) and loaded on the ABI PRISM 3700 DNA analyzer (Perkin-Elmer, Forster City, CA, USA). Resulting chromatograms were trimmed to eliminate vector sequences. Gene identification of clones was performed by a rapid and comprehensive homology analysis of the sequenced ESTs using Blast and Smith-Waterman algorithms with NCBI, Unigene, Swiss-Prot/TrEMBL (GeneBio, Geneva, SW, USA), and Derwent patent (Alexandria, VA, USA) databases, and accelerated hardware (TimeLogic, Reno, NV, USA).
Northern blots
A 503 bp PCR fragment of RPTPz (GenBank accession No. NM_002851 bp 614-1117) was cloned into pGEM-T easy (Promega, Madison, WI, USA). The vector was linearized and DIG-labeled antisense RNA run-off transcripts were generated by T7 RNA polymerase according to the manufacturer's instructions (DIG RNA Labeling Kit SP6/T7, Roche, Basel, Switzerland). Total RNA (20 mg) derived from tumor and normal brain samples were electrophoresed on a 1% agarose gel containing 6% formaldehyde (w/v). RNA was blotted onto a nylon membrane (Roche, Basel, Switzerland) by transfer for 16 h and fixed by baking for 30 min at 1201C. Hybridization with DIG-labeled antisense RNA probe (100 ng/ml) was carried out for 16 h at 501C in a buffer containing 50% formamide. The blot was washed twice at RT in a buffer containing 2 Â SSC, 0.1% SDS and twice at 501C with 0.2 Â SSC, 0.1% SDS. The blot was incubated with alkaline phosphatase-labeled anti-digoxigenin antibodies (Roche, Basel, Switzerland) and the signals were detected on X-ray film by incubation with CSPD (Roche, Basel, Switzerland) following the manufacturer's protocol. Subsequently, semiquantitative, densitometric analysis was performed using the Optiquant software (Packard Bioscience, Meriden, CT, USA). The rRNA signal as well as the signal of all three splice variants combined was determined after subtraction of background noise and the ratio the RPTPz/rRNA was calculated.
Immunohistochemistry
Paraffin sections, 4 mm thick, were dewaxed using standard histological procedures. Immunohistochemical staining was performed using the Vectastain ABC Kit (Vector, Burlingame, CA, USA). Sections were blocked using goat serum for 1 h at room temperature. Incubation with a monoclonal antibody against RPTPz (BD Transduction Laboratories, Lexington, KY, USA) diluted 1 : 200 in phosphate-buffered saline solution was performed at 41C overnight. Detection of bound antibody was performed according to the manufacturer's instructions (Vector, Burlingame, CA, USA) using a biotinylated goat antirabbit secondary antibody and 3,3 0 -diaminobenzidine tetrahydrochloride as substrate.
RNA interference (RNAi)
RNA oligos were ordered from Dharmacon Res. Inc. (Lafayette, CO, USA). The following sequences were used: RPTPz sense: AAA UGC GAA UCC UAA AGC GUU, RPTPz antisense: AAC GCU UUA GGA UUC GCA UUU. The primers were designed according to Elbashir et al. (2001) . As control, oligos sequences unrelated to RPTPz were used. Control sense: GGA CUU UCU GCC ACU CUA CUU, control antisense: GUA GAG UGG CAG AAA GUC CUU. The annealing of siRNAs was monitored by gel electrophoresis using Metaphor agarose which can separate small fragments (Biowhittaker, Walkersville, MD, USA). Cells were grown in 60 mm dishes to a confluence of 60-70%. The following day, cells were transfected with annealed siRNA using Effectene (Qiagen, Chatsworth, CA, USA) and 2 mg of siRNA. After 24 h, cells were harvested for protein extraction and migration assay. The transfection efficiency was monitored using an FITC-labeled DNA oligonucleotide (Sequitur Inc., New York, NY, USA) that was not homologous to RPTPz.
Western blot analysis
Protein was isolated by lysing the D566 and G122 cells with RIPA buffer (50 mm MOPS, 0.2 mm DTT, 300 mm EDTA, 1 m EGTA, 100 mm Na 3 VO 4 , 500 mm MgCl 2 , 500 mm NaF, 0.4% NP40) and freshly added Protease Inhibitor Cocktail 500 Â (Clontech, Palo Alto, CA, USA). Protein concentrations were determined using the BCA-200 protein assay (Pierce, Rockford, IL, USA) following the manufacturer's protocol. Proteins were separated using SDS/PAGE and transferred onto a nitrocellulose membrane (Schleicher and Schuell, Inc. Keene, NH, USA). After blocking the membrane with 10% nonfat dry milk in PBS, it was incubated with anti-RPTP beta mouse anti-human antibody (Transduction Laboratories, Lexington, KY, USA) in a 1 : 250 dilution at RT for 1 h. Incubation with secondary antibody, horseradish peroxidasecoupled rabbit anti-mouse IgG (Amersham Pharmacia Biotechnology, Little Chaltant, UK) was carried out for 1 h at RT. Detection followed with the ECL Western blotting detection kit (Amersham Pharmacia Biotechnology, Little Chaltant, UK). Subsequently, semiquantitative, densitometric analysis was performed using the Optiquant software (Packard Bioscience, Meriden, CT, USA). The RPTPz signal as well as the signal of the loading control (ras) was determined after subtraction of background noise and the ratio RPTPz/21Ras was calculated.
Migration assay
The migration assay was performed using the ChemoTx Disposable Chemotaxis system (Neuroprobe, Gaithersburg, MD, USA). Cells were incubated 24 h before the migration assay in starvation media (DMEM, 0.1% BSA). Cells were harvested, washed three times with starvation media and seeded on the filter following the manufacturer's protocol. For the glioblastoma cell lines G122 and D566, we used a pore size of 8 mm. In the upper well, 10000 cells/well were added. The lower wells contained DMEM, 5% FBS (FBS used as chemoattractant) or DMEM, no FBS for background calculation if not otherwise indicated. The assay was carried out for 2.5 h. The filters were stained using the Diff.-Quick dye kit (Dade Behring AG, Dudingen, Switzerland) and cells were quantified using ImagePro software (Version 4.1.0.0, Media Cybernetics, LP). Incubation with different concentrations of Ptn (Sigma, St Louis, MO, USA) was performed for 15 min at RT prior to the migration assay. Cells were washed following the incubation and the migration assay was performed as described above. For each assay condition, the background migration was subtracted by measuring the mean of 12 wells with no FBS. For each experimental condition, the mean of 24 individual wells was calculated.
Proliferation assay
Cellular proliferation was measured by the Celltiter-Glo luminescent cell viability assay (Promega, Madison, WI, USA). The number of viable cells in culture was measured based on a quantification of the ATP present, which signals the presence of metabolically active cells. The assay was performed according to the manufacturer's protocol.
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